desoximetasone Side Effects
Also known as: Topicort
Analysis of 18,159 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
18,159
Death-Related
4,534
25.0% of reports
Hospitalizations
6,570
36.2% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 4,534 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| SYSTEMIC LUPUS ERYTHEMATOSUS | 2,085 |
| GLOSSODYNIA | 2,013 |
| TYPE 2 DIABETES MELLITUS | 2,008 |
| DUODENAL ULCER PERFORATION | 1,986 |
| HAND DEFORMITY | 1,968 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 1,945 |
| RHEUMATOID ARTHRITIS | 1,938 |
| PSORIATIC ARTHROPATHY | 1,935 |
| HELICOBACTER INFECTION | 1,932 |
| FIBROMYALGIA | 1,926 |
| SYNOVITIS | 1,891 |
| WOUND | 1,889 |
| FATIGUE | 1,879 |
| INFUSION RELATED REACTION | 1,874 |
| RASH | 1,874 |
| HYPOAESTHESIA | 1,862 |
| HEPATIC ENZYME INCREASED | 1,858 |
| PEMPHIGUS | 1,854 |
| HYPERTENSION | 1,852 |
| PERICARDITIS | 1,831 |
Reactions in Hospitalization Reports
Top reactions in 6,570 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| FATIGUE | 3,117 |
| PAIN | 2,865 |
| RHEUMATOID ARTHRITIS | 2,863 |
| SYSTEMIC LUPUS ERYTHEMATOSUS | 2,851 |
| SWELLING | 2,775 |
| ARTHRALGIA | 2,771 |
| ABDOMINAL DISCOMFORT | 2,765 |
| RASH | 2,744 |
| ALOPECIA | 2,731 |
| SYNOVITIS | 2,725 |
| DRUG INEFFECTIVE | 2,703 |
| HAND DEFORMITY | 2,624 |
| OFF LABEL USE | 2,621 |
| PEMPHIGUS | 2,605 |
| GLOSSODYNIA | 2,604 |
| JOINT SWELLING | 2,595 |
| PERICARDITIS | 2,583 |
| ARTHROPATHY | 2,553 |
| HYPERSENSITIVITY | 2,552 |
| DUODENAL ULCER PERFORATION | 2,517 |
Nearby — Related Medications
What the FAERS Data Reveals About desoximetasone Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 18,159 voluntary reports linked to desoximetasone and its brand equivalents (Topicort), spanning 2004 through 2025. Of those, 4,534 (25.0%) listed death as an outcome and 6,570 (36.2%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 89% were female and 11% male; age distribution skews toward 18-44, with 5,980 reports in that bracket. The single most reported reaction is drug ineffective with 9,774 submissions, followed by pain and fatigue.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.